BERLIN (AP) — German biotech company CureVac has filed a patent infringement lawsuit against rival BioNTech for work that it says contributed to the development of the BioNTech-Pfizer coronavirus vaccine. BioNTech said its work is original and it plans to “vigorously” contest the claim. CureVac last year reported disappointing results from late-stage testing of its own first-generation COVID-19 shot. The company said Tuesday it was seeking “fair compensation” from BioNTech for the alleged infringement but doesn’t “intend to take legal action that impedes the production, sale or distribution” by BioNTech and partner Pfizer of their successful vaccine. Both CureVac and BioNTech have worked to develop the messenger RNA technology employed in their respective vaccines.
BE PART OF THE CONVERSATION
KIFI Local News 8 is committed to providing a forum for civil and constructive conversation.
Please keep your comments respectful and relevant. You can review our Community Guidelines by clicking here
If you would like to share a story idea, please submit it here.